Brentuximab Vedotin in Combination with Nivolumab in Relapsed or Refractory Hodgkin Lymphoma: 3-Year Study Results

This phase I-II study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). BV and Nivo with staggered or concurrent dosing were active and well tolerated when used as first salvage therapy in patients with r/r cHL.